ASH 2020 | TRANSCEND-CLL-04: 18-month follow-up of liso-cel for R/R CLL
William Wierda
• 1 Dec 2020
William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an update on the Phase I TRANSCEND-CLL-004 study (NCT03331198), investigating lisocabtagene maraleucel (liso-cel) as a treatment for relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), after a median follow-up of 18 months. The follow-up study reported that liso-cel treatment resulted in a high rate of undetectable minimal residual disease with rapid and durable responses. No late or delayed adverse effects were identified in the longer follow-up period. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
